Close
Company Search
Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Hutchmed (HCM) Share News

12345678910

IN BRIEF: Hutchmed lung cancer treatment Orpathys approved in China

14th Jan 2025 12:07

Hutchmed (China) Ltd - Hong Kong-based biopharmaceutical firm - Says its lung cancer treatment Orpathys has received full approval in China for adult patients. It has been developed in collaboration with AstraZeneca PLC, with Hutchmed leading in China and AZ leading outside of China. The drug was approved by the China National Medical Products Administration for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer. The approval was based on data from the confirmatory phase 3B clinical trial. Read More

LONDON MARKET OPEN: Stocks green but "policy uncertainties mount"

14th Jan 2025 09:02

(Alliance News) - Stock prices in London opened higher on Tuesday ahead of important US producer price inflation data due this afternoon. Read More

Hutchmed China disposes of 45% stake in Shanghai joint venture

2nd Jan 2025 10:46

(Alliance News) - Hutchmed (China) Ltd on Thursday said it has agreed to divest a 45% stake in Shanghai Hutchison Pharmaceuticals Ltd to GP Health Service Capital Co Ltd and Shanghai Pharmaceuticals Holding Co Ltd, for a total of around USD608 million. Read More

LONDON BRIEFING: Chrysalis settles claims with Revolution Beauty

2nd Jan 2025 07:48

(Alliance News) - London's FTSE 100 is set to open the year in the green, with a series of manufacturing purchasing managers' index readings the first hurdle for equities in 2025. Read More

IN BRIEF: Hutchmed to get Takeda milestone payment

13th Dec 2024 10:04

Hutchmed (China) Ltd - Hong Kong-based biopharmaceutical firm - Is to receive a USD10 million milestone payment from partner Takeda Pharmaceutical Co Ltd. Takeda receives a national reimbursement recommendation for the Fruzaqla cancer treatment in Spain this month. It is the first national reimbursement recommendation in Europe for the drug. "We are delighted for both our partner, Takeda, and patients in Spain who will now be able to receive reimbursement for this innovative treatment. This is an important step forward in improving patient access across Europe more broadly," Hutchmed Chief Executive Officer Weiguo Su says. "It also underscores our ongoing collaboration with Takeda and reinforces our shared commitment to addressing the needs of patients with metastatic colorectal cancer." Read More

LONDON BRIEFING: Sterling suffers as UK economy in surprise shrink

13th Dec 2024 07:43

(Alliance News) - London's FTSE 100 is called to open higher on Friday, shaking off poor UK data, a sharp decline in Asian equities, and weaker trade in the US overnight. Read More

Hutchmed China injection approval could be a "paradigm shift"

3rd Dec 2024 12:19

(Alliance News) - Hutchmed China Ltd on Tuesday reported it was granted conditional approval in China for an injection to treat endometrial cancer. Read More

Hutchmed to get payment from Takeda as Fruzaqla launched in Japan

22nd Nov 2024 10:00

(Alliance News) - Hutchmed (China) Ltd on Friday said it will receive a milestone payment from Takeda Pharmaceutical Co Ltd after Takeda launched Hutchmed's Fruzaqla in Japan. Read More

Hutchmed China receives first milestone payment for Takeda drug sales

31st Oct 2024 12:02

(Alliance News) - Hutchmed (China) Ltd on Thursday said it will receive a USD20 million payment from its partner Takeda Pharmaceutical Co Ltd which achieved a net sales milestone. Read More

TOP NEWS: AstraZeneca's Tagrisso plus Orpathys shows promising results

16th Oct 2024 09:52

(Alliance News) - Hutchmed China Ltd on Wednesday said that Tagrisso plus Orpathys showed a high clinically meaningful response rate in patients with a form of lung cancer. Read More

AIM WINNERS & LOSERS: Windward rises; Hutchmed recovers

10th Oct 2024 10:20

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Thursday. Read More

Takeda Pharmaceutical says Fruzaqla cancer drug gets Japan backing

24th Sep 2024 08:49

(Alliance News) - Takeda Pharmaceutical Co Ltd on Tuesday said it landed an approval for its Fruzaqla drug in Japan. Read More

Hutchmed "disappointed" as it withdraws fruquintinib application

30th Aug 2024 12:24

(Alliance News) - Hutchmed (China) Ltd announced on Friday that it has voluntarily withdrawn its supplemental new drug application for fruquintinib in China. Read More

Hutchmed confident of full year guidance for oncology and immunology

31st Jul 2024 14:41

(Alliance News) - Hutchmed (China) Limited on Wednesday said it remains on track to meet full year guidance for its oncology/immunology business, despite a fall in revenue. Read More

UK earnings, trading statements calendar - next 7 days

24th Jul 2024 14:45

Read More

IN BRIEF: Hutchmed's tazemetostat given priority review in China

5th Jul 2024 19:08

Hutchmed (China) Ltd - Hong Kong-based pharmaceutical company - Says new drug application for tazemetostat given priority review by the China National Medical Products Administration. Tazemetostat was developed by Epizyme Inc for the treatment of adult patients with relapsed or refractory follicular lymphoma. Drug was given accelerated approval in the US for certain patients with R/R FL and certain patients with advanced epithelioid sarcoma. Also approved in Japan for certain patients with R/R FL. The decision was supported by a phase II bridging study in China, and clinical studies conducted by Epizyme outside China. Tazemetostat was approved for use in Macau in 2023 and Hong Kong in 2024. Read More

IN BRIEF: Hutchmed China notes Takeda obtains EU approval for Fruzaqla

24th Jun 2024 10:00

Hutchmed (China) Ltd - Hong Kong-headquartered biopharmaceutical company - Notes that Takeda Pharmaceuticals Co Ltd received a notification from the European Commission that it has approved Fruzaqla, alias fruquintinib, as a monotherapy for adults with metastatic colorectoral cancer who have been previously treated with available standard therapies. Takeda has the exclusive worldwide license to develop, commercialise and manufacture fruquintinib outside of mainland China. Read More

Hutchmed celebrates "promising" results for sovleplenib in China

17th Jun 2024 10:32

(Alliance News) - Hutchmed (China) Ltd on Monday said its phase 3 trial of sovleplenib showed "consistent benefits" in adults with autoimmune disorder primary immune thrombocytopenia or ITP. Read More

IN BRIEF: Hutchmed (China) begins trial of menin inhibitor HMPL-506

7th Jun 2024 18:13

Hutchmed (China) Ltd - Hong Kong-headquartered biopharmaceutical company - Says that it has initiated Phase I clinical trial of its menin inhibitor HMPL-506 in patients with hematological malignancies in China. The first patient received their first dose on May 31. "This is a Phase I, multicenter, open-label clinical study to evaluate the safety, pharmacokinetics and efficacy of HMPL-506 in patients with hematological malignancies. The study is divided into two phases, a dose escalation phase and a dose expansion phase. The study is expected to enroll at least 60 patients," Hutchmed says. HMPL-506 is a novel, investigational, selective small molecule inhibitor for oral administration targeting the menin protein, it explains. Read More

IN BRIEF: Hutchmed China Simon To leaves role, succeeded by Dan Eldar

17th May 2024 17:58

Hutchmed (China) Ltd - Hong Kong-headquartered biopharmaceutical company - Chair Simon To retires from his role as chair, succeeded by Dan Eldar, effective immediately. Former chair To agrees to serve as strategic advisor to Hutchmed and will continue to contribute to the company "on significant matters". In a separate release, the company highlights Sovleplenib phase 3 data in adult patients with primary immune thrombocytopenia who have received at least one prior line of standard therapy. ITP is an autoimmune disease characterised by a low platelet count, purpura, and hemorrhagic episodes caused by antiplatelet autoantibodies. Hutchmed will present the data in mid-June in Madrid. Read More

12345678910
FTSE 100 Latest
Value8,809.74
Change53.53